Are there any recent updates or announcements from ATYR regarding their clinical trials?

Yes, aTyr Pharma (ATYR) has made several recent updates and announcements regarding their clinical trials. Here are some of the key highlights:

1. **Completion of Phase 3 EFZO-FIT Study**: aTyr Pharma announced the completion of the Phase 3 EFZO-FIT study for efzofitimod in pulmonary sarcoidosis, with the last patient completing their final visit on July 22, 2025.
2. **Topline Results Expected in Q3 2025**: The company expects to report topline results from the EFZO-FIT study in the third quarter of 2025.
3. **Positive Interim Results from Phase 2 Study**: aTyr Pharma reported positive interim results from its Phase 2 study of efzofitimod for treating systemic sclerosis-related interstitial lung disease (SSc-ILD), highlighting clinically significant improvements in patients.
4. **Upcoming Investor Conferences**: aTyr Pharma will present at upcoming investor conferences in May and June 2024, with discussions on their progress and future plans to develop first-in-class medicines.
5. **Inclusion in Russell 2000 and Russell 3000 Indexes**: The company is set to be included in the Russell 2000 and Russell 3000 indexes, effective June 27, 2025, marking its recognition among the largest publicly traded U.S. companies.

These updates demonstrate aTyr Pharma's ongoing commitment to advancing its clinical trials and its lead therapeutic candidate, efzofitimod, for the treatment of pulmonary sarcoidosis and other interstitial lung diseases.